Latest news with #Diclofenac
Mint
3 days ago
- Health
- Mint
7 common medicines that may secretly harm your heart health, reveals heart surgeon
Your heart works tirelessly, beating over 100,000 times a day to keep you alive, yet it is often taken for granted. With rising stress, sedentary lifestyles, unhealthy eating habits, and poor sleep, heart problems are becoming more common than ever, even among younger people. While many are aware that smoking, high cholesterol, and lack of exercise can hurt heart health, few realize that certain everyday medicines might be quietly adding to the risk. From pills we pop for a headache or cold to drugs for chronic conditions, some of them could strain the heart in unexpected ways. Yes, there are a few common medications that, when misused or taken long-term, may actually do your heart more harm than good. Here are some common medicines that may take a toll on your heart, leading to serious complications like high blood pressure, heart attack, heart failure, and even stroke: Over-the-counter pain relievers like Diclofenac, Ibuprofen, and Nimesulide are widely used medicines for treating pain, fever, and inflammation. But what many people do not realize is that these drugs can quietly affect your heart health. "Long-term or high-dose use of NSAIDs can lead to high blood pressure, fluid retention, and increase the risk of heart attack or stroke, especially in those with existing heart issues," warns Dr Swarup Swaraj Pal, Senior Consultant Cardiovascular and Thoracic Surgeon at Gleneagles Hospitals. A study published in the British Medical Journal found that taking NSAIDs, even for just a week, can significantly raise your risk of a heart attack. To deal with seasonal cold and flu, decongestants like phenylephrine and pseudoephedrine are commonly used. However, they may do more than good. "Decongestants can constrict blood vessels, leading to an increase in heart rate and blood pressure," explains Dr Swarup. For individuals with hypertension or pre-existing cardiac conditions, this can be dangerous. The Annals of Emergency Medicine reports that these drugs can overstimulate the cardiovascular system, increasing the risk of heart attack or other complications. While antidepressants can help improve mental health, some types, especially tricyclic antidepressants like Amitriptyline or SSRIs like Fluoxetine, can potentially affect your heart rhythm. "These drugs may increase heart rate and, in people with structural heart disease or arrhythmias, lead to palpitations or irregular heartbeats," says Dr Swarup. If you have any known heart issues, it is important to discuss potential side effects with your psychiatrist or cardiologist before starting or changing antidepressant medication. Some medications used to manage type 2 diabetes, such as Pioglitazone, are known to cause fluid retention. In some cases, this can lead to heart failure. It is particularly risky in people who already have any heart health problems. If you are on anti-diabetic medication, make sure your doctor keeps a close watch on your heart health. Antibiotics like Azithromycin and Clarithromycin are often prescribed for respiratory or bacterial infections. However, they can interfere with your heart's electrical activity. "These drugs can lead to arrhythmias, especially when taken alongside other heart-sensitive medicines," notes Dr Swarup. They are not dangerous for everyone, but in people with heart conditions or those taking multiple medications, the combination could be risky. Corticosteroids, often referred to simply as steroids, are commonly prescribed for asthma, arthritis, and allergic conditions because of their anti-inflammatory properties. But they can come with serious cardiovascular side effects. According to a study in the Canadian Respiratory Journal, oral corticosteroids were linked to a higher risk of high blood pressure and acute myocardial infarction (heart attack). Why? These drugs can cause the body to retain sodium and fluid, leading to increased pressure in blood vessels and added strain on the heart.
Time of India
6 days ago
- Business
- Time of India
Asston Pharmaceuticals IPO to list today. GMP signals healthy premium on debut
Pharmaceutical exporter Asston Pharmaceuticals is all set to debut on the BSE SME platform on Wednesday with strong retail and institutional participation boosting pre-listing sentiment. The company's Rs 27.56 crore IPO, which was open between July 9 and 11, is commanding a grey market premium (GMP) of Rs 30, translating to a 24% premium over the issue price of Rs 123 per share. The IPO was entirely a fresh issue of 22.41 lakh shares. Incorporated in 2019, Asston Pharmaceuticals manufactures and exports a wide range of pharmaceutical formulations, including tablets, syrups, capsules, and sachets. The company focuses on key therapeutic categories such as analgesics, antibiotics, antifungals, and vitamins, with products like Albendazole, Diclofenac, and Ferrovit Syrup forming part of its portfolio. Asston operates on both direct sales and contract manufacturing models and holds certifications from central and state FDA, NQA, and follows Quality Management System (QMS) standards. As of July 2025, it has a workforce of 52 employees, including 6 on contract. Financial Snapshot The company posted robust growth in FY25, with revenue up 62% year-on-year to Rs 25.61 crore, and PAT rising 218% to Rs 4.33 crore. EBITDA also jumped to Rs 6.16 crore from Rs 2.55 crore in the previous year. With a 24% GMP, strong financials, and growing demand for Indian pharma exports, Asston's listing is expected to see healthy investor interest, though the SME segment's volatility remains a caveat. All eyes will now be on the stock's opening tick on Wednesday. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Economic Times
6 days ago
- Business
- Economic Times
Asston Pharmaceuticals IPO to list today. GMP signals healthy premium on debut
Live Events Financial Snapshot (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Pharmaceutical exporter Asston Pharmaceuticals is all set to debut on the BSE SME platform on Wednesday with strong retail and institutional participation boosting pre-listing sentiment. The company's Rs 27.56 crore IPO, which was open between July 9 and 11, is commanding a grey market premium (GMP) of Rs 30, translating to a 24% premium over the issue price of Rs 123 per IPO was entirely a fresh issue of 22.41 lakh in 2019, Asston Pharmaceuticals manufactures and exports a wide range of pharmaceutical formulations, including tablets, syrups, capsules, and company focuses on key therapeutic categories such as analgesics, antibiotics, antifungals, and vitamins, with products like Albendazole, Diclofenac, and Ferrovit Syrup forming part of its operates on both direct sales and contract manufacturing models and holds certifications from central and state FDA, NQA, and follows Quality Management System (QMS) standards. As of July 2025, it has a workforce of 52 employees, including 6 on company posted robust growth in FY25, with revenue up 62% year-on-year to Rs 25.61 crore, and PAT rising 218% to Rs 4.33 crore. EBITDA also jumped to Rs 6.16 crore from Rs 2.55 crore in the previous a 24% GMP, strong financials, and growing demand for Indian pharma exports, Asston's listing is expected to see healthy investor interest, though the SME segment's volatility remains a caveat. All eyes will now be on the stock's opening tick on Wednesday.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Time of India
25-06-2025
- Business
- Time of India
Nimulid Strong appoints Rajkummar Rao as its new brand ambassador
Mankind Pharma , India's pharmaceutical company, has announced actor Rajkummar Rao as the new brand ambassador for its flagship brand, Nimulid Strong for Pain Relief Gel and Spray. This strategic partnership aims to firmly establish Nimulid Strong as the trusted " Neck Pain Specialist " for targeted pain relief, highlighting its remarkable ability to provide relief in just two minutes, while leveraging Rao's relatable appeal and the product's powerful 2X Diclofenac formulation . Rao, celebrated for his versatile roles in critically acclaimed and commercially successful films embodies the spirit of those who refuse to let pain dictate their lives, the company stated in a press release. His genuine connection with everyday individuals makes him the perfect choice to represent Nimulid Strong, a brand committed to empowering people to overcome challenges and lead pain-free lives , it added. "We're absolutely thrilled to welcome Rajkummar Rao to the Mankind Pharma family, representing Nimulid Strong. Rajkummar's authenticity, relatability, and incredible craft resonate deeply with our audience, making him the ideal choice to represent Nimulid Strong – 'The Neck Pain Specialist,'' said Joy Chatterjee, vice president, sales and marketing head, consumer business unit, Mankind Pharma. 'Our mission is to empower individuals to overcome these challenges and lead pain-free lives, and with Nimulid Strong, they can experience relief in as little as two minutes. With Rajkummar on board, we're confident we'll strengthen Nimulid Strong's position as a trusted and highly effective solution for quick, localised relief,' Chatterjee added. Rao shared his thoughts on this association, stating, "I'm excited to be a part of the Mankind Pharma family and to endorse a brand like Nimulid Strong that offers such effective and quick relief, helping people get back to their lives without pain holding them back." This partnership underscores Mankind Pharma's dedication to providing fast and effective solutions for contemporary pain, particularly neck pain caused by digital fatigue, poor posture, and muscle stress, the company stated.
News18
28-05-2025
- Health
- News18
How One Drug Wiped Out 99% Of India's Vultures In Less Than 20 Years
Curated By : Parishmita Saikia Translation Desk Last Updated: May 28, 2025, 16:21 IST Ingesting traces of Diclofenac caused acute kidney failure in vultures, but despite its ban in India in 2006, illegal use persists. (News18) Once a common sight circling above carcasses, vultures have all but vanished from India's skies. Research by the University of Chicago revealed that between 1990 and 2007, 99% of the vulture population in India perished. This collapse has had dire consequences: in the absence of these natural scavengers, infections from decaying animal carcasses have spread, reportedly contributing to five lakh human deaths. The Diclofenac Disaster The principal culprit behind this ecological tragedy is the veterinary drug Diclofenac, commonly used in the 1990s to treat livestock. Though effective, Diclofenac residues in cattle carcasses proved lethal to vultures. Ingesting even trace amounts caused acute kidney failure in the birds. Despite India banning the drug in 2006, its illegal use still persists. Alarming Decline Rates India was once home to an estimated 40 to 50 million vultures. By 2007, that number had dropped catastrophically. Populations of: White-rumped vultures (Gyps bengalensis) declined by 99.9% declined by 99.9% Indian vultures (Gyps indicus) by 95% by 95% Slender-billed vultures (Gyps tenuirostris) by 97% This marks one of the fastest recorded declines of any bird species in history. WWF India Poster Threats Beyond Diclofenac Even after the ban, vulture populations have not rebounded. Vultures breed slowly, laying just one egg annually, and face numerous other threats including: Electrocution from power lines Collisions with wind turbines Injuries from kite strings Their absence has triggered a rise in feral dog and crow populations, increasing the risk of rabies and other zoonotic diseases. Cultural And Economic Fallout Swipe Left For Next Video View all The decline also impacts cultural practices. The Parsi community, which conducts sky burials dependent on vulture scavenging, has had to alter funeral rites. The economic toll is staggering too. Between 2000 and 2005, losses due to vulture extinction were estimated at $69.4 billion annually, affecting industries like leather production. Since 2016, India has undertaken conservation efforts, including the reintroduction of protected vulture species into the wild. However, experts stress that community engagement and stringent enforcement of Diclofenac bans are critical for reversing this crisis. News lifestyle How One Drug Wiped Out 99% Of India's Vultures In Less Than 20 Years
